Caribou Biosciences/$CRBU
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Ticker
$CRBU
Sector
Primary listing
Employees
97
Headquarters
Website
CRBU Metrics
BasicAdvanced
$165m
-
-$1.41
2.28
-
Price and volume
Market cap
$165m
Beta
2.28
52-week high
$3.54
52-week low
$1.22
Average daily volume
1.9m
Financial strength
Current ratio
6.221
Quick ratio
6.099
Long term debt to equity
25.151
Total debt to equity
26.413
Profitability
EBITDA (TTM)
-114.156
Gross margin (TTM)
-726.59%
Net profit margin (TTM)
-1,189.14%
Operating margin (TTM)
-1,046.91%
Effective tax rate (TTM)
0.41%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-34.69%
Return on equity (TTM)
-83.46%
Valuation
Price to revenue (TTM)
13.956
Price to book
1.58
Price to tangible book (TTM)
1.58
Price to free cash flow (TTM)
-1.538
Free cash flow yield (TTM)
-65.01%
Free cash flow per share (TTM)
-1.079
Growth
Revenue change (TTM)
12.96%
Earnings per share change (TTM)
-12.79%
3-year revenue growth (CAGR)
-8.63%
3-year earnings per share growth (CAGR)
-7.34%
What the Analysts think about CRBU
Analyst ratings (Buy, Hold, Sell) for Caribou Biosciences stock.
CRBU Financial Performance
Revenues and expenses
CRBU Earnings Performance
Company profitability
CRBU News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs